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Abstract 8-Cl-cAMP, a cAMP analogue that antagonizes type
I cAMP-dependent protein kinase, is a novel anti-tumor agent
presently under investigation in clinical trials. Herein we report
the effects of this agent on epidermal growth factor receptor
expression and degradation in human KB cancer cells. Exposure
to 10 WM 8-Cl-cAMP for 48 h induced a 65% increase in
epidermal growth factor receptor surface expression while the
receptor synthesis was 22-fold enhanced. Analysis of epidermal
growth factor-dependent receptor internalization in 8-Cl-cAMP-
treated cells showed a higher endocytosis rate as well as an
accelerated degradation which occurred together with an
increased receptor ubiquitination. The enhanced degradation of
epidermal growth factor receptor correlated with the lack of
epidermal growth factor-induced proliferation and mitogen-
activated protein kinase stimulation. The disregulation of
epidermal growth factor receptor internalization and ubiquitin-
dependent degradation could underlay a new mechanism of the
anti-tumor activity of 8-Cl-cAMP suggesting its combination
with agents that disrupt epidermal growth factor receptor
signalling.
z 1999 Federation of European Biochemical Societies.
Key words: cAMP analogue; Protein kinase A; Epidermal
growth factor receptor; Endocytosis; Ubiquitin;
Mitogen-activated protein kinase
1. Introduction
Epidermal growth factor (EGF) is a polypeptide which has
a strong mitogenic activity both in vitro and in vivo [1] and
exerts its e¡ects through a cell surface receptor. The speci¢c
binding of EGF to the extracellular domain of the 170 kDa
EGF receptor (EGF-R) triggers dimerization of the receptor
and activation of its intrinsic tyrosine kinase activity [2]. The
latter event leads to the receptor autophosphorylation fol-
lowed by the recruitment and activation of multiple signalling
proteins which initiate a complex series of intracellular events
regulating the cell responsiveness to the growth stimuli [2,3].
A key point in the EGF-induced mitogenic cascade is the
stimulation of mitogen-activated protein kinase (MAPK)
that transmits the signal into the nucleus leading to gene ex-
pression regulation and, ¢nally, to the induction of cell pro-
liferation [4,5]. Together with the activation of the signal
transduction cascade, receptor/ligand complexes are rapidly
internalized via the endocytic pathway and are routed to ly-
sosomes where the receptors are degraded [6]. The latter event
causes receptor down-regulation and attenuates the signal
transduction cascade [6,7].
Several studies have suggested that modulation of the ex-
pression of peptide growth factor receptors (PGF-R) is a com-
mon event in tumor cells that have been exposed to low con-
centrations of cytotoxic drugs or to biological agents [8^12].
We have previously reported that cytostatic concentrations of
K2-recombinant interferon (IFNK) induced up-regulation of
EGF-R expression in human epidermoid cancer KB cells
[12] and that this e¡ect potentiated the mitogenic activity of
EGF on these cells [13]. 8-Cl-cAMP, a synthetic cAMP ana-
logue which can be considered an antagonist of type I cAMP-
dependent protein kinase (PKA-I), is a novel anti-tumor agent
that has undergone extensive preclinical evaluation and is
presently under investigation in clinical trials on cancer pa-
tients [14^17]. 8-Cl-cAMP changes the ratio between the two
regulatory subunits, RI and RII, of PKA [18]. In particular, it
has been shown that this agent reduces the expression and
activity of RI/PKA-I which is overexpressed in tumor cells
and is enhanced in normal cells upon exposure to mitogenic
stimuli [18,19]. On the other hand, 8-Cl-cAMP increases RII/
PKA-II which has been correlated with cell growth inhibition
and di¡erentiation [18,19]. It has also been demonstrated that
8-Cl-cAMP interferes with growth factor autocrine pathways
and the growth factor-induced cell transformation [20]. Fur-
thermore, 8-Cl-cAMP synergizes with a blocking anti-EGF-R
monoclonal antibody (MAb) on the growth inhibition of tu-
mor cells [21]. The concomitant and selective disruption of
di¡erent growth regulating pathways, by the use of pharma-
cological or biological agents, is presently an important tool
for the development of new anti-tumor therapeutic strategies
[22^24].
In this study we have investigated the EGF/EGF-R signal
pathway in KB cells which are growth inhibited upon 8-Cl-
cAMP treatment and are dependent on EGF for their prolif-
eration [25]. Speci¢cally, we have studied the e¡ects of 8-Cl-
cAMP on EGF-R cell surface expression and synthesis. We
have found a discrepancy in magnitude between the EGF-R
up-regulated expression on the cell membrane and the in-
crease in receptor synthesis induced by 8-Cl-cAMP. There-
fore, we have evaluated the e¡ects of the cAMP analogue
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on EGF-R internalization and on ubiquitin-dependent degra-
dation which has been described as a possible pathway for
EGF-R down-regulation [7]. Furthermore, we have investi-
gated the e¡ect of 8-Cl-cAMP on the EGF-R transduction
pathway studying the EGF-induced MAPK activation and
cell proliferation in KB cells.
2. Materials and methods
2.1. Cell culture and cell proliferation assays
The human epidermoid carcinoma KB cell line (ATCC, Rockville,
MD, USA) was grown in Dulbecco’s Modi¢ed Eagle Medium
(DMEM) supplemented with 10% heat-inactivated fetal bovine serum
(Gibco, Grand Island, NY, USA), penicillin (50 U/ml), streptomycin
(500 Wg/ml) and 4 mM glutamine, in a humidi¢ed atmosphere of 95%
air and 5% CO2 at 37‡C. KB cells throughout all the experiments have
been maintained in serum-containing medium and no EGF depriva-
tion has been performed to enhance the EGF e¡ects on cell growth or
protein phosphorylation. For cell growth assays, 105 cells were seeded
in triplicate in 6-multiwell plates. 8-Cl-cAMP (sodium salt, provided
by K.P. Flora, National Cancer Institute, Bethesda, MD, USA) or
EGF (Sigma, St. Louis, MO, USA) were added at indicated concen-
trations after 3 h of seeding and every 48 h thereafter when medium
change was performed. At the indicated time points, cell growth as-
sessment was performed by haemocytometric cell count and a trypan
blue viability assay, following gentle trypsinization.
2.2. [125I]EGF-binding
The cells were seeded in 24-multiwell plates at 2U104 cells/well and
treated as described above. 8-Cl-adenosine (BioLog Life Science In-
stitute, Bremen, Germany) was used here and throughout all further
experiments at a concentration of 1 WM which is the IC50 for KB cells
after 48 h of treatment. The treated and untreated cells were incu-
bated overnight in serum-free medium (i.e. DMEM supplemented
with non-essential amino acids and vitamines). The cells were washed
twice with ice-cold phosphate bu¡ered saline (PBS) in the presence of
1 mg/ml of bovine serum albumin (BSA) and further incubated for 4 h
at 4‡C with 200 Wl/well binding bu¡er (DMEM, HEPES 25 mM, BSA
1 mg/ml) containing 30 000 cpm/well of [125I]EGF (164 WCi/mg, Amer-
sham, Buckinghamshire, UK) and increasing concentrations of unla-
belled EGF, as previously described [8]. Cells were washed four times
with PBS/BSA and lysed in 0.5 Wl/well of 20 mM HEPES, 1% Triton
X-100, 10% glycerol. The cell-associated radioactivity was counted in
a Beckman Q-counter. The value of the EGF-R-binding a⁄nity and
the receptor number were determined by Scatchard analysis as pre-
viously described [8].
2.3. EGF-R live cell radioimmunoassay (RIA)
KB cells were seeded in 96-multiwell plates at 5U103 cells/well and
exposed for 48 h to 8-Cl-cAMP or 8-Cl-adenosine. After overnight
incubation in serum-free medium, 100 Wl 5% BSA (w/v) in DMEM
was added to each well. After 60 min of incubation at 37‡C, the cells
were washed with DMEM/BSA and 50 Wl of appropriately diluted
anti-EGF-R MAb 108.1 (kindly donated by Prof. J. Schlessinger,
Department of Pharmacology, NYU Medical Center, NY, USA)
was added to each well for 3 h at 4‡C. The cells were washed twice
with 5% PBS/BSA (w/v) and 125I-labelled sheep anti-mouse IgG
(75 000 cpm in 50 Wl, Amersham) was added to each well. Following
a 60 min incubation (at 37‡C), the cells were washed three times with
PBS/BSA 5% (w/v), adsorbed with a cotton swab and the radioactiv-
ity was counted in a Beckmann Q-counter, as previously described [13].
2.4. EGF-R endocytosis
The cells were seeded in 24-multiwell plates at 2U104 cells/well and
treated as described above. After overnight incubation in serum-free
medium, cells were washed twice with ice-cold PBS/BSA and exposed
for 1 h at 4‡C to binding bu¡er containing 4 ng/ml [125I]EGF
(V120 000 dpm/well). Then, untreated or 8-Cl-cAMP-treated cells
were washed three times with ice-cold PBS/BSA and exposed to bind-
ing bu¡er, pre-warmed at 37‡C, containing 0.1 WM non-labelled EGF
for the indicated times at 37‡C and washed twice with PBS/BSA at
4‡C. The cells were incubated twice with acid bu¡er (0.2 M acetic
acid, pH 2.5 and 0.2 M NaCl) for 3 min at 4‡C and lysed. Acid
sensitive and acid resistant cell-associated radioactivity was deter-
mined by a Q-counter. The % EGF-R endocytosis was calculated for
each time of exposure to EGF as:
acid resistant 125IEGF radioactivity
acid resistant acid sensitive 125IEGF radioactivityU100
2.5. Metabolic labelling of EGF-R and solubilization of intact cells
KB cells were starved for 30 min at 37‡C in methionine-free me-
dium and then incubated for 3 h in methionine-free medium in the
presence of 200 WCi/ml L-[35S]methionine (1300 Ci/mM, Amersham).
For cell extract preparation, cells were washed twice with ice-cold
PBS/BSA, scraped and centrifuged in lysis bu¡er (20 mM, Tris(hy-
droxymethyl) methylamine-HCl (Tris), pH 7.4, 100 mM NaCl, 1%
NP-40, 0.5% sodium deoxycholate, 5 mM MgCl2, 0.1 mM pepstatin,
0.1 mM antipain, 0.1 mM chymostatin, 0.2 mM leupeptin, 0.4 mg/ml
aprotinin and 0.5 mg/ml soybean trypsin inhibitor) as previously de-
scribed [13]. The samples were equalized on radioisotope incorpora-
tion by L-counting the radioactivity contained in trichloroacetic acid
(TCA)-precipitated aliquots.
2.6. Immunoprecipitation, electrophoresis and Western blot analysis
Supernatants from L-[35S]methionine-labelled cells were subjected to
immunoprecipitation with 25 Wg anti-EGF-R 108.1 MAb for 90 min
at 4‡C with 50 Wl of protein A-Sepharose conjugated. The immuno-
precipitated were separated by 8% SDS-PAGE and then ¢xed and
dried before autoradiography [13].
For Western blot analysis, equal amounts of protein extracts, de-
termined by the Lowry method using serum albumin as standard,
were immunoprecipitated and separated as described above. The
blots, obtained from electrotransfer to nitrocellulose ¢lter, were
probed for 12 h with anti-EGF-R 108.1 or anti-phosphotyrosine
4G10 (Upstate Biotechnology, Lake Placid, NJ, USA) or anti-ubiq-
uitin (DAKO, Glostrup, DK, USA) antibodies. The immunocom-
plexes were detected with an enhanced chemiluminescence (ECL) sys-
tem from Amersham.
2.7. MAPK assay
The cell pellets, after two washes with ice-cold PBS, were suspended
in bu¡er H (50 mM L-glycerophosphate, 1.5 mM ethyleneglycol-bis-
(L-aminoethyl ether) N,N,NP,NP-tetraacetic acid (EGTA), 0.1 mM
Na3V04, 1 mM dithiotreitol (DTT), 30 Wg/ml leupeptin, 5 Wg/ml apro-
tinin, 5 Wg/ml pepstatin), homogenized and centrifuged at 10000Ug
for 10 min. The resulting supernatants were processed for a MAPK
assay using myelin basic protein (MBP, Sigma) and [Q32P]ATP (Amer-
sham) as substrates. 10 Wl of cell extract was added to an assay
mixture (15 Wl) containing 50 mM L-glycerophosphate, 1.5 mM
EGTA, 0.1 mM Na3V04, 1 mM DTT, 15 mM MgCl2, 0.66 WM
PKA inhibitor (Sigma), MBP at 0.5 mg/ml and 22.5 WM [Q32-P]ATP
(5^20 cpm/fmol). After 30 min incubation at 30‡C, the reaction mix-
tures were spotted onto phosphocellulose ¢lters (Whatman P81) and
washed three times in 175 mM phosphoric acid. Filters were air-dried
and then counted by liquid scintillation using Omni£uor/toluene (Du-
Pont, New England Nuclear, Boston, MA, USA).
3. Results
3.1. E¡ects of 8-Cl-cAMP on EGF-R expression and synthesis
8-Cl-cAMP inhibits the KB cell growth without any cyto-
toxic e¡ect [16] while EGF induces proliferation both in vitro
and in vivo [25]. We found a dose- and time-dependent in-
crease of [125I]EGF binding sites on KB cells after 8-Cl-cAMP
treatment (Fig. 1A). In fact, increased EGF-binding was de-
tectable after 24 h of treatment with 5^10 WM 8-Cl-cAMP,
reached a peak after 48 h and decreased beyond this time
point as compared with untreated cells at the same time points
(Fig. 1A).
It was previously shown that 8-Cl-cAMP can be hydrolyzed
to 8-Cl-adenosine by the serum-phosphodiesterases and 5P-
nucleotidase and has been hypothesized that this molecule
can be indeed responsible for the e¡ects of 8-Cl-cAMP
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[26,27]. However, further investigations have demonstrated
that the e¡ects of 8-Cl-cAMP are not mediated by its metab-
olite [19,28]. EGF-R up-regulation induced by 8-Cl-cAMP
was not due to the metabolite because, in our experimental
conditions, 8-Cl-adenosine did not modify the EGF-binding
(Fig. 1B and C). Scatchard plot analysis of EGF-binding data
revealed two classes of EGF receptors (Fig. 1B and C) with
Kd values of 0.04^0.055 nM (high a⁄nity) and 2.2^2.8 nM
(low a⁄nity), respectively (Fig. 1C). An about 65% increase of
both low and high a⁄nity EGF-R number was detectable
after 48 h exposure of KB cells to 8-Cl-cAMP without any
change in the receptor a⁄nity (Fig. 1B and C). In order to
determine whether the increase of EGF-binding on the cell
surface was really due to an increase of EGF-R proteins
and not to an unmasking of unoccupied EGF binding sites,
we have performed a live cell RIA experiment using the anti-
EGF-R MAb 108.1 that is directed against an epitope outside
the EGF binding site. Again, this assay shows that 8-Cl-
cAMP increased the number of EGF-Rs on KB cells while
no e¡ects were demonstrated in 8-Cl-adenosine-treated cells
(Fig. 1D).
In order to evaluate whether the synthesis of EGF-R was
modi¢ed by 8-Cl-cAMP, we have performed an immunopre-
cipitation of the EGF-R after metabolic labelling with L-
[35S]methionine. We have found that 18 h and 36 h of treat-
ment with 8-Cl-cAMP induced a 18 and a 22-fold increase of
EGF-R synthesis, respectively (Fig. 2A and B). Therefore, the
up-regulation induced by 8-Cl-cAMP at the tumor cell surface
was likely due to the increased synthesis of EGF-R. However,
the two e¡ects resulted much di¡erent in magnitude because
the 22-fold enhancement of receptor synthesis resulted only in
a 65% increase in receptor expression at the tumor cell sur-
face.
3.2. E¡ects of EGF and 8-Cl-cAMP on EGF-R endocytosis and
ubiquitin-dependent degradation
In order to investigate the discrepancy between the extents
of the magnitude of EGF-R surface up-regulation and the
increased synthesis, we have investigated if the internalization
rate of EGF-R was also modi¢ed by 8-Cl-cAMP in KB cells.
We have found that 8-Cl-cAMP induced an increase in the
rate of EGF-R endocytosis as compared with untreated con-
trol cells (Fig. 3A). EGF-R internalization was again not af-
fected by KB cell treatment with 8-Cl-adenosine (Fig. 3A).
Since EGF-R is not recycled on the cell membrane and deg-
radation follows endocytosis [2,7], we have investigated by
Western blotting analysis if 8-Cl-cAMP could modulate also
the whole cell content of EGF-R in KB cells following expo-
sure to EGF. We found that 8-Cl-cAMP alone induced about
a 2-fold increase of the EGF-R expression in KB cells (Fig.
3B). The exposure to EGF alone for 5^30 min caused a slight
decrease in the EGF-R electrophoretic mobility shift (Fig. 3B)
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Fig. 1. E¡ects of 8-Cl-cAMP on EGF-R expression on the KB cell surface. (A) E¡ects of di¡erent concentrations of 8-Cl-cAMP on [125I]EGF-
binding. After medium withdrawal, fresh medium without 8-Cl-cAMP or with 1 WM (v), 5 WM (R) and 10 WM (b) 8-Cl-cAMP was added.
[125I]EGF-speci¢c binding was expressed as a percentage of that measured in control cultures for each time point. [125I]EGF-speci¢c binding
was determined in the presence of 100 nM unlabelled EGF. The data show means of three separate experiments of triplicate determinations.
S.E. never exceeded 10%. (B) Scatchard analysis of EGF-binding data on untreated controls and 8-Cl-cAMP-treated KB cells. [125I]EGF-bind-
ing to untreated (a) or 48 h 10 WM 8-Cl-cAMP-treated (b) or 1 WM 8Cl-adenosine-treated (E) KB cells. [125I]EGF-binding has been performed
in the presence of di¡erent concentrations of [125I]EGF. Points, averages from triplicate determinations. (C) Number and Kd of the low and
high a⁄nity EGF binding sites evaluated as described above. (D) Anti-EGF-R MAb binding curve on KB cells. Binding of anti-EGF-R MAb
108.1 to untreated (a) or 10 WM 8-Cl-cAMP- (b) or 1 WM 8-Cl-adenosine-treated (E) KB cells as assessed by live cell RIA, performed through
the use of [125I]sheep anti-mouse IgG and expressed as cpm/104 cells. The data show means of three separate experiments of triplicate determi-
nations. Bars, S.D.
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that could be due to EGF-R covalent modi¢cations such as
phosphorylation or ubiquitination, as previously demon-
strated [7]. The further exposure of KB cells to EGF reduced
the receptor expression. As shown in Fig. 3B, after 6 h of
treatment with EGF, a 2-fold decrease of EGF-R cell content
was recorded. In 8-Cl-cAMP-treated cells, a 6-fold reduction
of EGF-R expression was already detectable after 3 h of ex-
posure to EGF (Fig. 3B). Moreover, 8-Cl-cAMP had no e¡ect
on the EGF-induced tyrosine phosphorylation of the receptor
(Fig. 3C).
EGF-induced down-regulation of the EGF-R is followed by
receptor degradation that can be partially ubiquitin-dependent
[7]. We have therefore studied if the rapid fall of the receptor
levels in 8-Cl-cAMP-treated cells was associated to an in-
creased ubiquitination of EGF-Rs. We have indeed found
that the formation of ubiquitin-EGF-R complexes following
exposure to EGF was signi¢cantly increased in 8-Cl-cAMP-
treated cells as compared with an untreated control. As shown
in Fig. 3D, a rapid increase in EGF-R ubiquitination was
evident after exposure of 8-Cl-cAMP-treated cells to EGF
for 5 min and correlated with EGF-R tyrosine phosphoryla-
tion (Fig. 3C), while in untreated cells a slight increase was
observed after 15 min of treatment with EGF. At later times,
a progressive loss of ubiquitin-EGF-R complexes correlated
with EGF-R degradation (Fig. 3B). Therefore, 8-Cl-cAMP
increased the EGF-induced internalization and ubiquitin-de-
pendent degradation of EGF-R.
3.3. E¡ects of 8-Cl-cAMP on the EGF-induced cell
proliferation and MAPK activity
In order to assess if the changes in EGF-R expression and
degradation induced by 8-Cl-cAMP could modify the biolog-
ical response of KB cells to EGF, we have evaluated the
interaction between 8-Cl-cAMP and EGF on the cell prolif-
eration. 48 h treatment with 10 WM 8-Cl-cAMP induced 50%
growth inhibition without cytotoxicity (Fig. 4A), as demon-
strated by a trypan blue assay (data not shown), or major
morphological changes as demonstrated by FACS and elec-
tron microscopic analysis (A. Budillon, unpublished results).
On the other hand, 1 nM EGF, which was the concentration
approximately equivalent to the Kd value of the low a⁄nity
receptors (Fig. 1C), brought about the maximal stimulation of
KB cell growth after 4 days of treatment (Fig. 4A). The pro-
liferative response to EGF was, however, completely abol-
ished in the presence of 10 WM 8-Cl-cAMP and this e¡ect
was time-dependent (Fig. 4A and B). The induction of
MAPK activity is a crucial event in the signalling cascade
which transmits the EGF-mediated mitogenic e¡ect into the
nucleus through phosphorylation of transcription factors and
regulation of gene expression [4]. We have therefore investi-
gated whether 8-Cl-cAMP could interfere with the EGF in-
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Fig. 3. E¡ects of EGF and 8-Cl-cAMP on EGF-R endocytosis, pro-
tein levels, ubiquitination and phosphorylation in KB cells. (A) We
have evaluated the e¡ects of 8-Cl-cAMP on the endocytosis of
EGF-R in KB cells. 2U105 cells/well were seeded in 24-multiwell
plates. Cells were grown for 48 h in the absence (b) or presence of
10 WM 8-Cl-cAMP (b) or 1 WM 8-Cl-adenosine (E). [125I]EGF endo-
cytosis was measured as described in Section 2. The data show
means of three separate experiments of triplicate determinations.
S.E. were always less than 10%. (B) Expression, (C) tyrosine phos-
phorylation and (D) ubiquitination of EGF-R have been assessed
by Western blot analysis as described in Section 2. Cells have been
cultured for the indicated times with 10 WM 8-Cl-cAMP and/or
10 nM EGF. Cell extracts, equalized by protein determination, were
immunoprecipitated with EGF-R polyclonal antiserum and then
subjected to hybridization with anti-EGF-R 108.1, anti-phosphotyr-
osine 4G10 and anti-ubiquitin MAbs, respectively. The ECL (Amer-
sham) detection system was used.
Fig. 2. E¡ects of EGF and 8-Cl-cAMP on the EGF-R synthesis in
KB cells. Immunoprecipitation of EGF-R with anti-EGF-R MAb
108.1 after metabolic labelling of KB cells with L-[35S]methionine.
(A) The samples were equalized on radioisotope incorporation by L-
counting the radioactivity contained in TCA-precipitated aliquots.
After PAGE of immunoprecipitates and autoradiography of dried
gels, EGF-R appears as a 170 kDa band. Cells have been exposed
for 6 h, 18 h and 36 h to 10 WM 8-Cl-cAMP as shown in the ¢gure.
The experiment shown is one of three experiments that gave similar
results. (B) Laser scanning of the bands corresponding to EGF-R in
the immunoprecipitation experiment expressed as realtive level and
arbitrary units derived from a common software (Gel-Pro Analyzer,
Media Cybernetics, Silver Spring, MD, USA).
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duction of MAPK activity. Treatment of KB cells with EGF
for 10 min induced an almost 100% increase in the MAPK
activity (Fig. 4B). This e¡ect was however completely lost in
KB cells which have been exposed for 48 h to 10 WM 8-Cl-
cAMP (Fig. 4B). Therefore, the 8-Cl-cAMP-induced disregu-
lation of EGF-R internalization and degradation is associated
to a lack of EGF-induced mitogenic response and to a block
in the EGF-R signalling cascade.
4. Discussion
Cellular receptors for peptide growth factors and other
down-stream signal transducers are important regulators of
normal and tumor cell proliferation [1]. EGF-R has been
found to be overexpressed on neoplastic cells of epithelial
origin and has been implicated in the process of cell growth
and transformation [1].
8-Cl-cAMP, a synthetic cAMP analogue which can be con-
sidered an antagonist of PKA-I, inhibits the cell proliferation
without exerting cytotoxic e¡ects [14^16,28]. Moreover, 8-Cl-
cAMP is under clinical evaluation in phase I trials as anti-
cancer agent [17]. Several reports showed that 8-Cl-cAMP
may interfere with growth factor autocrine pathways and
growth factor-induced transformation [20,29,30]. On the basis
of these considerations, we have investigated the e¡ects of 8-
Cl-cAMP on the EGF-R expression in KB cells, which are
dependent on EGF for their proliferation [25]. We have found
that growth inhibition induced by 8-Cl-cAMP was paralleled
by an about 65% increase of EGF-R expression on the cell
membrane. We have previously shown that also IFNK or
cytotoxic drugs used at cytostatic concentrations, such as cy-
tosine arabinoside and 5-aza-2P deoxy cytidine, increase the
expression of EGF-R on epithelial cancer cells [8,9,12,13].
Therefore, such an e¡ect could be ascribed to a homeostatic
response of cancer cells to the growth inhibitory stimuli in-
duced by the drugs. However, in the present study, a discrep-
ancy in the magnitude of 8-Cl-cAMP e¡ects on the EGF-R
synthesis and expression was described. These e¡ects occurred
together with an increase of EGF-induced EGF-R down-reg-
ulation and degradation. Moreover, the EGF-mediated ubiq-
uitination of EGF-R was dramatically increased in 8-Cl-
cAMP-treated KB cells. The internalization and the subse-
quent degradation process is an important mechanism of
modulation of EGF-R expression and function. It is possible
that the ubiquitin pathway may account, at least in part, for
the degradation of cell surface membrane proteins. Also ubiq-
uitination may serve as a regulator of cell proliferation since
the human oncogene tre-2 bares a de-ubiquitinating property
[31]. Recently, it has been demonstrated that EGF-R is ubiq-
uitinated after EGF-mediated internalization [7]. However, it
has also been reported that a mutant EGF-R that fails to be
ubiquitinated is only partially defective in the EGF-stimulated
down-regulation [7]. Therefore, ubiquitination is not an obli-
gatory requirement for EGF-R degradation and the redun-
dancy of pathways for EGF-R down-regulation may re£ect
the importance of receptor degradation for the attenuation of
signal transduction. In our experimental model, the preserva-
tion of the catalytic activity of EGF-R in 8-Cl-cAMP-treated
cells correlated with the increased ubiquitination of the recep-
tor. The requirement of an active kinase for the ubiquitination
process has been described for the protein kinase C family and
for the receptor tyrosine kinase c-kit [32]. In the case of EGF-
R, the kinase activity is required for EGF-stimulated ubiqui-
tination although the role of the receptor tyrosine phospho-
rylation has not been completely established [6,7]. Interest-
ingly, a direct interaction between cAMP-dependent protein
kinase PKA-I isoenzyme and EGF-R has been recently de-
scribed [33]. Since 8-Cl-cAMP can be considered an antago-
nist of PKA-I, it may be involved in the disruption of this
association leading to modulation of the EGF-R expression
and tra⁄cking. Moreover, in our experimental model, an in-
creased receptor degradation was paralleled by the loss of
mitogenic response and of MAPK activity, induced by EGF
in KB cells. Therefore, the increase of EGF-R ubiquitination
could be involved in a general mechanism of negative regula-
tion of receptor-mediated activation of a growth promoting
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Fig. 4. E¡ects of 8-Cl-cAMP on the proliferative response of KB
cells to EGF and on MAPK activity. (A) Cells have been exposed
for 48 h to di¡erent concentrations of EGF in the presence (b) or
absence (a) of 10 WM 8-Cl-cAMP. Cell growth was expressed as a
percentage of untreated controls. The data show means of three sep-
arate experiments of triplicate determinations. The S.E. never ex-
ceeded 10%. (B) Cells have been cultured for the indicated times in
the presence of the following agents: (a) 10 nM EGF, (b) 10 WM
8-Cl-cAMP, (F) 10 nM EGF+10 WM 8-Cl-cAMP. The cell growth
was expressed as a percentage of untreated controls. The data show
means of three separate experiments of triplicate determinations.
The S.E. never exceeded 10%. (C) A MAPK assay performed after
di¡erent times of exposure to 10 nM EGF on untreated (a) or
10 WM 8-Cl-cAMP-treated (b) KB cells, as described in Section 2.
The data were expressed as inorganic phosphates (Pi) pmoles trans-
ferred/min/mg of protein lysate. The data show means of three sepa-
rate experiments of triplicate determinations. Bars, S.D.
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pathway. Furthermore, it is important to consider that the
EGF-R up-regulation induced by other agents, such as
IFNK, was associated with a sensitization of tumor cells to
the growth promoting activity of EGF [13].
The understanding of the molecular mechanisms regulating
the expression and function of PGF-Rs in tumor cells exposed
to cytostatic agents could be useful for the design of innova-
tive approaches to tumor cell growth inhibition, combining
anti-proliferative agents and bioreagents that target such re-
ceptors [21^24]. Moreover, the pharmacological increase of
the ubiquitination process, as induced by 8-Cl-cAMP, could
be a further approach for the control of PGF-R-dependent
tumor cell growth.
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